Form 15F-12B TELUS International (Cda

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File Number: 001-39968

 

 

TELUS International (Cda) Inc.

 

(Exact name of registrant as specified in its charter)

 

Floor 5, 510 West Georgia Street
Vancouver, BC V6B 0M3
Telephone: (604) 695-3455

 

 

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Subordinate Voting Shares, no par value

 

(Title of each class of securities covered by this Form)

 

None  

 

(Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)		☒
Rule 12g-4(a)(2)		☐
Rule 12h-3(b)(1)(i)		☒
Rule 12h-3(b)(1)(ii)		☐
Rule 15d-6		☐
Rule 15d-22(b)		☐

 

Approximate number of holders of record as of the certification or notice date: One (1)

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, TELUS International (Cda) Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date: November 10, 2025

 

TELUS International (Cda) Inc.
By:	/s/ Michel Belec
Name:	Michel Belec
Title:	Chief Legal Officer and Corporate Secretary

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• ZenaTech acquires ESM Software to expand enterprise SaaS portfolio
• SCHMID Group cuts profit margin outlook, keeps revenue target above €100M
• FibroBiologics wins Australian patent for cannabidiol and cell therapy combo